Expand all sections

Pacritinib

Epjevy

Extended indication Patients with myelofibrosis who have thrombocytopenia
Therapeutic value No estimate possible yet
Total cost 945,000.00
Registration phase Clinical trials

Product

Active substance Pacritinib
Domain Hematology
Reason of inclusion New medicine (specialité)
Main indication Myeloproliferative disorders
Extended indication Patients with myelofibrosis who have thrombocytopenia
Proprietary name Epjevy
Manufacturer Cti
Mechanism of action JAK tyrosine kinase inhibitor
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)
Additional remarks Tyrosine kinase inhibitor gericht tegen JAK2 en FLT3

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date 2025
Expected Registration 2026
Orphan drug Yes
Registration phase Clinical trials
Additional remarks Pacritinib was al eerder ingediend in juni 2016 maar werd teruggetrokken in maart 2017 vanwege tijdtekort om nieuwe data in de aanvraag te includeren. De aanvraag die in juli 2017 is ingediend is in februari 2019 teruggetrokken met als reden dat CTI niet is staat is data te leveren binnen de procedurele tijdslijn om de vragen van de EMA te adresseren.

Therapeutic value

Current treatment options Ruxolitinib
Therapeutic value No estimate possible yet
Duration of treatment Median 15.6 month / months
Frequency of administration 1 times a day
Dosage per administration 400 mg

Expected patient volume per year

Patient volume

21 - 33

Market share is generally not included unless otherwise stated.
References NKR; Mesa et al. Lancet Haematol. 2017 May;4(5):e225-e236.
Additional remarks 118 diagnoses in 2016. Trombocytopenie komt voor bij 18 tot 28% van de myelofibrosis patiënten (21 tot 33 patiënten).

Expected cost per patient per year

Cost 30,000.00 - 40,000.00
References GIPdatabank
Additional remarks De vergoeding per patiënt in 2015 voor de huidige behandelmethode met ruxolitinib was €32.174,00.

Potential total cost per year

Total cost

945,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No
Additional remarks geen fase III studies voor andere indicaties dan in de horizonscan

Other information

There is currently no futher information available.